Afficher la couverture 'Circulating tumor DNA strongly predicts efficacy of chemotherapy plus immune checkpoint inhibitors in patients with advanced gastro-esophageal adenocarcinoma | Tougeron, David' en grand format
/5

0 avis

Circulating tumor DNA strongly predicts efficacy of chemotherapy plus immune checkpoint inhibitors in patients with advanced gastro-esophageal adenocarcinoma

Archive ouverte

Tougeron, David | Louvet, Christophe | Desramé, Jérôme | Evesque, Ludovic | Angelergues, Antoine | Carnot, Aurélien | Breysacher, Gilles | Zaanan, Aziz | Etchepare, Nicolas | Mabro, May | Kaluzinski, Laure | Petorin, Caroline | Chibaudel, Benoist | Aparicio, Thomas | Bodere, Anaïs | Rinaldi, Yves | Le Malicot, Karine | Emile, Jean-François | Lepage, Côme | Baures, Aurélia | Djamai, Hanane | Taly, Valérie | Laurent-Puig, Pierre

Edité par CCSD ; Nature -

International audience. Efficacy of 2nd line treatment in advanced gastric or gastro-esophageal junction (GEJ) adenocarcinoma remains limited with no identified strong predictor of treatment efficacy. We evaluated the prognostic value of circulating tumor DNA (ctDNA) in predicting the efficacy of immune checkpoint inhibitors (ICI) plus chemotherapy in the randomized PRODIGE 59-FFCD 1707-DURIGAST trial.

Consulter en ligne

Suggestions

Du même auteur

FOLFIRI Plus Durvalumab with or Without Tremelimumab in Second-Line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: The PRODIGE 59-FFCD 1707-DURIGAST Randomized Clinical Trial

Archive ouverte | Tougeron, David | CCSD

International audience. © 2024 American Medical Association. All rights reserved.Importance: Efficacy of second-line chemotherapy in advanced gastric or gastrooesphageal junction (GEJ) adenocarcinoma remains limited...

Clinico-biological factors predicting the benefit of the LV5FU2 maintenance strategy as a first-line therapy in patients with metastatic pancreatic cancer

Archive ouverte | Boisteau, Emeric | CCSD

International audience. Introduction Predictive markers of LV5FU2 maintenance benefit after first-line induction with FOLFIRINOX in patients with metastatic pancreatic cancer are necessary to select patients who wil...

PRODIGE 59-DURIGAST trial: A randomised phase II study evaluating FOLFIRI + Durvalumab ± Tremelimumab in second-line of patients with advanced gastric cancer

Archive ouverte | Evrard, Camille | CCSD

International audience. Gastric or gastro-oesophageal junction (GEJ) adenocarcinomas present poor overall survival (OS). First-line chemotherapy regimen for patients with HER2-negative tumours is based on a doublet ...

Chargement des enrichissements...